Breast Cancer

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.

Transitioning into survivorship and relocating to a new city prompts reflection on identity, fear and freedom, showing survivorship as choosing to live forward.

March weather becomes a metaphor for survivorship as a mother describes anxiety, relief and uncertainty patients with cancer feel between scans.

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.

My daughter is happy to tell her story so that others can learn that there is hope in the face of despair.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive basal-type cancers.

Genentech announces FDA acceptance of giredestrant plus Afinitor for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer treatment.

Dr. Sara Tolaney discusses how Trodelvy plus Keytruda improves progression-free survival in patients with PD-L1+ metastatic triple-negative breast cancer.

Researchers identified nine genetic markers that help HER2-positive breast cancer resist treatment, paving the way for more personalized patient care.

After cancer, I learned how to weigh environmental risks and make informed decisions for long-term survivorship and peace of mind.

Researchers developed a tool to predict chemotherapy response for patients with triple-negative breast cancer.

My intent in writing this blog is to make sure that other people whose loved ones have cancer understand just how amazing it is to be given short respites from being a patient.

Laura Yeager reflects on losses from theft and cancer, showing how resilience grows and gratitude emerges even after life's hardest setbacks.

CURE spoke with breast cancer survivor Mary Royal about her cancer journey in a multipart interview.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

NCCN Guidelines now recommend Trodelvy as a category 1 first-line option for PD-L1–negative metastatic TNBC following phase 3 trial results.

The FDA granted Breakthrough Therapy status to zovegalisib plus Faslodex for patients with PIK3CA-mutated HR+/HER2- advanced breast cancer.

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Clinical trial data shows that the protein CD47 may predict how well evorpacept works for patients with metastatic breast cancer.

Biotin supplements used for cancer-related hair loss may interfere with key blood tests, risking inaccurate results and altered care decisions.

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.